Long-term study following people with Parkinson's disease in France
Records symptoms, treatments and blood samples over time in people with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: French Parkinson's Disease Cohort - NS-PARK
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Centre 01 ParisParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Trial code
- NCT04888364
- Record updated
- 20 August 2026
- Original description
The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.Read full original descriptionShow less
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.
Inclusion: Diagnosis of Parkinson's disease according to UK PD brain bak criteria; OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom; OR Subjects at risk of PD defined as :; No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015); AND for all participants; Affiliated to social security; Age > 10 years.
Exclusion: Subject under legal protection; Subject who do not consent to the research; for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment.